Shares of Amarin (AMRN) are on the rise on Monday after AstraZeneca (AZN) said that it is closing a Phase 3 clinical trial of a fish-oil-derived heart drug, Epanova, after an independent Data Monitoring Committee concluded it was unlikely to demonstrate a benefit to patients. Meanwhile, Acasti Pharma… To see the rest of the story go to thefly.com. (See Story Here):(https://www.thefly.com/permalinks/entry.php/id3017138/-Amarin-jumps-after-AstraZeneca-fish-oil-drug-trial-fails)
previous post